IBD Research to Advance with Boehringer Ingelheim New Partnerships

IBD Research to Advance with Boehringer Ingelheim New Partnerships
Boehringer Ingelheim recently announced a new collaboration with four leading U.S. scientific institutions to advance research and development of new therapeutic strategies for patients living with inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease. The four new partners of the company are the Massachusetts General Hospital, Icahn School of Medicine at Mount Sinai,

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *